348 related articles for article (PubMed ID: 25684650)
1. Evaluation of nitrogen-rich macrocyclic ligands for the chelation of therapeutic bismuth radioisotopes.
Wilson JJ; Ferrier M; Radchenko V; Maassen JR; Engle JW; Batista ER; Martin RL; Nortier FM; Fassbender ME; John KD; Birnbaum ER
Nucl Med Biol; 2015 May; 42(5):428-438. PubMed ID: 25684650
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and characterization of nitrogen-rich macrocyclic ligands and an investigation of their coordination chemistry with lanthanum(III).
Wilson JJ; Birnbaum ER; Batista ER; Martin RL; John KD
Inorg Chem; 2015 Jan; 54(1):97-109. PubMed ID: 25526533
[TBL] [Abstract][Full Text] [Related]
3. Labeling internalizing anti-epidermal growth factor receptor variant III monoclonal antibody with (177)Lu: in vitro comparison of acyclic and macrocyclic ligands.
Hens M; Vaidyanathan G; Welsh P; Zalutsky MR
Nucl Med Biol; 2009 Feb; 36(2):117-28. PubMed ID: 19217523
[TBL] [Abstract][Full Text] [Related]
4. DTPA complexation of bismuth in human blood serum.
Montavon G; Le Du A; Champion J; Rabung T; Morgenstern A
Dalton Trans; 2012 Jul; 41(28):8615-23. PubMed ID: 22678751
[TBL] [Abstract][Full Text] [Related]
5. Tuning the Kinetic Inertness of Bi
Fiszbein DJ; Brown V; Thiele NA; Woods JJ; Wharton L; MacMillan SN; Radchenko V; Ramogida CF; Wilson JJ
Inorg Chem; 2021 Jun; 60(12):9199-9211. PubMed ID: 34102841
[TBL] [Abstract][Full Text] [Related]
6. Assessment of PSMA targeting ligands bearing novel chelates with application to theranostics: Stability and complexation kinetics of
Kelly JM; Amor-Coarasa A; Nikolopoulou A; Kim D; Williams C; Vallabhajosula S; Babich JW
Nucl Med Biol; 2017 Dec; 55():38-46. PubMed ID: 29055836
[TBL] [Abstract][Full Text] [Related]
7. Yttrium-90 chelation properties of tetraazatetraacetic acid macrocycles, diethylenetriaminepentaacetic acid analogues, and a novel terpyridine acyclic chelator.
Stimmel JB; Stockstill ME; Kull FC
Bioconjug Chem; 1995; 6(2):219-25. PubMed ID: 7599265
[TBL] [Abstract][Full Text] [Related]
8. Bismuth-213 and actinium-225 -- generator performance and evolving therapeutic applications of two generator-derived alpha-emitting radioisotopes.
Morgenstern A; Bruchertseifer F; Apostolidis C
Curr Radiopharm; 2012 Jul; 5(3):221-7. PubMed ID: 22642390
[TBL] [Abstract][Full Text] [Related]
9. Boosting Bismuth(III) Complexation for Targeted α-Therapy (TAT) Applications with the Mesocyclic Chelating Agent AAZTA.
Horváth D; Vágner A; Szikra D; Trencsényi G; Demitri N; Guidolin N; Maiocchi A; Ghiani S; Travagin F; Giovenzana GB; Baranyai Z
Angew Chem Int Ed Engl; 2022 Oct; 61(43):e202207120. PubMed ID: 36073561
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic efficacy and toxicity of 225Ac-labelled vs. 213Bi-labelled tumour-homing peptides in a preclinical mouse model of peritoneal carcinomatosis.
Essler M; Gärtner FC; Neff F; Blechert B; Senekowitsch-Schmidtke R; Bruchertseifer F; Morgenstern A; Seidl C
Eur J Nucl Med Mol Imaging; 2012 Apr; 39(4):602-12. PubMed ID: 22237842
[TBL] [Abstract][Full Text] [Related]
11. Bismuth chelation for targeted alpha therapy: Current state of the art.
Franchi S; Di Marco V; Tosato M
Nucl Med Biol; 2022; 114-115():168-188. PubMed ID: 35753940
[TBL] [Abstract][Full Text] [Related]
12. Improved in vivo stability of actinium-225 macrocyclic complexes.
Deal KA; Davis IA; Mirzadeh S; Kennel SJ; Brechbiel MW
J Med Chem; 1999 Jul; 42(15):2988-92. PubMed ID: 10425108
[TBL] [Abstract][Full Text] [Related]
13. H
Kadassery KJ; King AP; Fayn S; Baidoo KE; MacMillan SN; Escorcia FE; Wilson JJ
Bioconjug Chem; 2022 Jun; 33(6):1222-1231. PubMed ID: 35670495
[TBL] [Abstract][Full Text] [Related]
14. Development of
Ondrák L; Ondrák Fialová K; Sakmár M; Vlk M; Bruchertseifer F; Morgenstern A; Kozempel J
Nucl Med Biol; 2024; 132-133():108909. PubMed ID: 38599144
[TBL] [Abstract][Full Text] [Related]
15. Progress in Targeted Alpha-Particle Therapy. What We Learned about Recoils Release from In Vivo Generators.
Kozempel J; Mokhodoeva O; Vlk M
Molecules; 2018 Mar; 23(3):. PubMed ID: 29510568
[TBL] [Abstract][Full Text] [Related]
16. Samarium-153 and lutetium-177 chelation properties of selected macrocyclic and acyclic ligands.
Stimmel JB; Kull FC
Nucl Med Biol; 1998 Feb; 25(2):117-25. PubMed ID: 9468026
[TBL] [Abstract][Full Text] [Related]
17. Streptavidin in antibody pretargeting. 5. chemical modification of recombinant streptavidin for labeling with the alpha-particle-emitting radionuclides 213Bi and 211At.
Wilbur DS; Hamlin DK; Chyan MK; Brechbiel MW
Bioconjug Chem; 2008 Jan; 19(1):158-70. PubMed ID: 18072725
[TBL] [Abstract][Full Text] [Related]
18. An Eighteen-Membered Macrocyclic Ligand for Actinium-225 Targeted Alpha Therapy.
Thiele NA; Brown V; Kelly JM; Amor-Coarasa A; Jermilova U; MacMillan SN; Nikolopoulou A; Ponnala S; Ramogida CF; Robertson AKH; Rodríguez-Rodríguez C; Schaffer P; Williams C; Babich JW; Radchenko V; Wilson JJ
Angew Chem Int Ed Engl; 2017 Nov; 56(46):14712-14717. PubMed ID: 28963750
[TBL] [Abstract][Full Text] [Related]
19. Chelating Rare-Earth Metals (Ln
Hu A; Simms ME; Kertesz V; Wilson JJ; Thiele NA
Inorg Chem; 2022 Aug; 61(32):12847-12855. PubMed ID: 35914099
[TBL] [Abstract][Full Text] [Related]
20. H2CHXdedpa and H4CHXoctapa-chiral acyclic chelating ligands for (67/68)Ga and (111)In radiopharmaceuticals.
Ramogida CF; Cawthray JF; Boros E; Ferreira CL; Patrick BO; Adam MJ; Orvig C
Inorg Chem; 2015 Feb; 54(4):2017-31. PubMed ID: 25621728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
